Already partnering with AZ and Boehringer Ingelheim in liver targets, the UK biotech sees potential to hit ‘undruggable’ CNS targets as well.
Servier has signed a deal with MiNA Therapeutics to develop novel small activating RNA (saRNA) therapies in neurological disorders.
The London-based biotech’s technology is based on the work of pioneering liver disease drug developer and surgeon Nagy
Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.
The company drew praise from the Trump administration as one of multiple companies announcing multibillion-dollar investments in US manufacturing and R&D.
The novel RAF/MEK inhibitor and FAK inhibitor are the first treatment approved specifically for KRAS-mutated recurrent low-grade serious ovarian cancer (LGSOC).
HTX-001 targeting the long non-coding RNA known as Wisper is being developed for non-obstructive hypertrophic cardiomyopathy. HAYA partnered with Lilly last year in obesity.
The Phase I results are the best to date among ANGPTL3-targeting candidates in the pipeline, but analysts will wait for further updates before predicting a likely winner.
HTX-001 targeting the long non-coding RNA known as Wisper is being developed for non-obstructive hypertrophic cardiomyopathy. HAYA partnered with Lilly last year in obesity.
Houman Ashrafian tells delegates at Swiss Biotech Day that ‘literally only two things matter in our industry – target credentialing and differentiated pharmacology. The rest is execution.’
